Stock Analysis on Net
Stock Analysis on Net

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Common-Size Balance Sheet: Assets

Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: assets

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents 8.25 10.63 11.35 12.78 10.93
Marketable securities 24.53 15.87 11.04 8.12 10.78
Accounts receivable, net 17.13 18.24 23.73 23.97 18.05
Inventories 7.80 8.22 7.67 11.17 9.56
Prepaid expenses and other current assets 1.17 1.41 1.31 0.94 2.61
Current assets 58.88% 54.37% 55.10% 56.98% 51.94%
Marketable securities 16.31 22.56 26.88 18.27 22.00
Property, plant, and equipment, net 12.53 12.88 13.69 18.77 19.52
Intangible assets, net 3.14 3.13 0.03 0.00 0.00
Deferred tax assets 7.79 5.90 3.45 5.00 5.57
Other noncurrent assets 1.34 1.15 0.85 0.98 0.98
Noncurrent assets 41.12% 45.63% 44.90% 43.02% 48.06%
Total assets 100.00% 100.00% 100.00% 100.00% 100.00%

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Regeneron Pharmaceuticals Inc. current assets as a percentage of total assets decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Property, plant, and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Regeneron Pharmaceuticals Inc. property, plant, and equipment, net as a percentage of total assets decreased from 2021 to 2022 and from 2022 to 2023.
Noncurrent assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Regeneron Pharmaceuticals Inc. noncurrent assets as a percentage of total assets increased from 2021 to 2022 but then decreased significantly from 2022 to 2023.